Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
33 hedge funds and large institutions have $401M invested in Day One Biopharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 33 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
29.33% more ownership
Funds ownership: 0% → 29.33% (+29%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA Capital Management
Boston,
Massachusetts
|
+$104M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$48.2M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$31.4M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$28M |
| 5 |
Janus Henderson Group
London,
|
+$27.1M |
Top Sellers
DAWN Hedge Fund Activity: Q2 2021 in Review
33 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q2 2021, worth a combined $401M.
Buyers outnumbered sellers: 33 funds opened new DAWN positions and 0 closed out — a net gain of 33 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $104M.
- 33 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $401M of Day One Biopharmaceuticals stock for Q2 2021.
- 33 funds opened new Day One Biopharmaceuticals positions in Q2 2021 and 0 closed out, a net change of +33 holders.
- The largest Day One Biopharmaceuticals buyer in Q2 2021 was RA Capital Management, an estimated $104M added.
Based on aggregated 13F filings for Q2 2021.